Global Pain Therapeutics Market to 2029 - Featuring Abbott Laboratories, AstraZeneca and GlaxoSmithKline Among Others
28. März 2022 07:33 ET
|
Research and Markets
Dublin, March 28, 2022 (GLOBE NEWSWIRE) -- The "Pain Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
Insights on the Cancer Pain Global Market to 2030 - Rising Healthcare Expenditure and Government Support Worldwide are Driving Growth
09. März 2022 04:58 ET
|
Research and Markets
Dublin, March 09, 2022 (GLOBE NEWSWIRE) -- The "Global Cancer Pain Market, By Drug Type, By Disease Indication, Estimation & Forecast, 2017 - 2030" report has been added to...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corporate History
21. Juni 2013 13:44 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 21, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Announces 2013 Fiscal Year End Conference Call on Monday, June 24, 2013
19. Juni 2013 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 19, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Pharmaceuticals Announces First Shipment of Generic Hydromorphone Product
13. März 2012 08:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 13, 2012 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today the initial shipment of hydromorphone hydrochloride 8 mg tablets, the generic...